Grifols FCF Margin
The Free Cash Flow Margin of Grifols (GRF.MC) as of Jul 26, 2026 is 8.29 %. In the previous year, Free Cash Flow Margin was 9.28 % — a change of -10.68% (lower).
Get this data via API
Financial Data API
FCF Margin
8.29 %
YoY
-10.68%
Last updated:
Free Cash Flow Margin of Grifols is 2026 8.29 % . Free Cash Flow Margin of Grifols was 2025 9.28 % . It decreases by -10.68% lower compared to the previous year.
Access this data via the Eulerpool API
Grifols Stock analysis
What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Grifols stock
Free Cash Flow Margin of Grifols is 8.29 % in 2026.
Access this data via the Eulerpool API
Margins — Grifols
All Key Metrics — Grifols
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth